Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020118245 - QUANTITATIVE CENTROSOMAL AMPLIFICATION SCORE TO PREDICT LOCAL RECURRENCE OF DUCTAL CARCINOMA IN SITU

Publication Number WO/2020/118245
Publication Date 11.06.2020
International Application No. PCT/US2019/065057
International Filing Date 06.12.2019
IPC
C12Q 1/00 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
G01N 33/50 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N 33/53 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
G01N 33/574 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
G06F 19/00 2018.01
GPHYSICS
06COMPUTING; CALCULATING OR COUNTING
FELECTRIC DIGITAL DATA PROCESSING
19Digital computing or data processing equipment or methods, specially adapted for specific applications
G06F 19/10 2011.01
GPHYSICS
06COMPUTING; CALCULATING OR COUNTING
FELECTRIC DIGITAL DATA PROCESSING
19Digital computing or data processing equipment or methods, specially adapted for specific applications
10Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
Applicants
  • GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. [US]/[US]
Inventors
  • MITTAL, Karuna
  • RIDA, Padmashree
  • ANEJA, Ritu
Agents
  • SCHWARTZ, Michael A.
  • KIRSCH, Gregory J.
Priority Data
62/776,14406.12.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) QUANTITATIVE CENTROSOMAL AMPLIFICATION SCORE TO PREDICT LOCAL RECURRENCE OF DUCTAL CARCINOMA IN SITU
(FR) SCORE QUANTITATIF D'AMPLIFICATION DES CENTROSOMES POUR PRÉDIRE LA RÉCURRENCE LOCALE D'UN CARCINOME CANALAIRE IN SITU
Abstract
(EN)
Embodiments may provide capability to predict the 10-year risk of local recurrence of ductal carcinoma in situ (DCIS) conditions or other non-invasive carcinomas in situ. Embodiments may evaluate the severity and frequency of numerical and structural CA present within DCIS, and may assign a quantitative centrosomal amplification score (CAS) to each sample. For example, a method of determining the risk profile of a carcinoma in situ in a patient may comprise determining severity and frequency of numerical and structural centrosome amplification present within a sample of a carcinoma in situ from the patient and determining at least one centrosome amplification score (CAS) value for the sample based on the determined severity and frequency of numerical and structural centrosome amplification in the sample, wherein the determined at least one CAS value provides a measure of a level of a 10-year risk of local recurrence associated with the carcinoma in situ.
(FR)
Des modes de réalisation peuvent permettre de prédire le risque à 10 ans de récurrence locale d'un carcinome canalaire in situ (CCIS) ou d'autres carcinomes in situ non invasifs. Des modes de réalisation peuvent évaluer la gravité et la fréquence d'amplification numérique et structurelle des centrosomes (CA) présente dans le CCIS, et peuvent attribuer un score d'amplification des centrosomes quantitatif (CAS) à chaque échantillon. Par exemple, un procédé pour déterminer le profil de risque d'un carcinome in situ chez un patient peut comprendre la détermination de la gravité et de fréquence de CA numérique et structurelle présente dans un échantillon d'un carcinome in situ prélevé chez le patient; et la détermination d'au moins un résultat de score d'amplification des centrosomes (CAS) pour l'échantillon, sur la base de la gravité et de la fréquence déterminées de la CA numérique et structurelle dans l'échantillon, l'au moins un résultat de score CAS déterminé fournissant une mesure du niveau du risque à 10 ans de récurrence locale associée au carcinome in situ.
Latest bibliographic data on file with the International Bureau